MA50391B1 - Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires - Google Patents

Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires

Info

Publication number
MA50391B1
MA50391B1 MA50391A MA50391A MA50391B1 MA 50391 B1 MA50391 B1 MA 50391B1 MA 50391 A MA50391 A MA 50391A MA 50391 A MA50391 A MA 50391A MA 50391 B1 MA50391 B1 MA 50391B1
Authority
MA
Morocco
Prior art keywords
diseases
pharmaceutical compositions
imidazo
compositions containing
inflammatory disorders
Prior art date
Application number
MA50391A
Other languages
English (en)
French (fr)
Other versions
MA50391A (fr
Inventor
David Amantini
Reginald Brys
René Galien
Der Plas Steven Van
Oscar Mammoliti
Sébastien Martina
Pieter Claes
Ghjuvanni Coti
Denis Annoot
Ramos Miriam López
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA50391A publication Critical patent/MA50391A/fr
Publication of MA50391B1 publication Critical patent/MA50391B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA50391A 2017-10-20 2018-10-11 Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires MA50391B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2018/077677 WO2019076716A1 (en) 2017-10-20 2018-10-11 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
MA50391A MA50391A (fr) 2021-04-21
MA50391B1 true MA50391B1 (fr) 2023-11-30

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50391A MA50391B1 (fr) 2017-10-20 2018-10-11 Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires

Country Status (30)

Country Link
US (3) US11564923B2 (cg-RX-API-DMAC7.html)
EP (2) EP4265254A3 (cg-RX-API-DMAC7.html)
JP (2) JP7292271B2 (cg-RX-API-DMAC7.html)
KR (1) KR102757425B1 (cg-RX-API-DMAC7.html)
CN (2) CN117534670A (cg-RX-API-DMAC7.html)
AR (1) AR113784A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018350592B2 (cg-RX-API-DMAC7.html)
CA (1) CA3079449A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020005200A2 (cg-RX-API-DMAC7.html)
DK (1) DK3697784T5 (cg-RX-API-DMAC7.html)
ES (1) ES2967432T3 (cg-RX-API-DMAC7.html)
FI (1) FI3697784T5 (cg-RX-API-DMAC7.html)
GB (1) GB201717260D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20231315T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063998T2 (cg-RX-API-DMAC7.html)
IL (2) IL273943B2 (cg-RX-API-DMAC7.html)
LT (1) LT3697784T (cg-RX-API-DMAC7.html)
MA (1) MA50391B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003863A (cg-RX-API-DMAC7.html)
MY (1) MY205443A (cg-RX-API-DMAC7.html)
PH (1) PH12020550230A1 (cg-RX-API-DMAC7.html)
PL (1) PL3697784T3 (cg-RX-API-DMAC7.html)
PT (1) PT3697784T (cg-RX-API-DMAC7.html)
RS (1) RS64800B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003516TA (cg-RX-API-DMAC7.html)
SI (1) SI3697784T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300377T1 (cg-RX-API-DMAC7.html)
TW (2) TWI805629B (cg-RX-API-DMAC7.html)
WO (1) WO2019076716A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002166B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
EP3976612A4 (en) * 2019-05-28 2023-04-26 Mankind Pharma Ltd NEW COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
JP2023503343A (ja) 2019-11-26 2023-01-27 プラクシス プレシジョン メディシンズ, インコーポレイテッド イオンチャネルモジュレーター
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
MX2024000517A (es) 2021-07-12 2024-01-31 Galapagos Nv Tratamiento de enfermedades inflamatorias.
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
WO2023161327A1 (en) * 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
JP7882100B2 (ja) * 2022-12-07 2026-06-30 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
EP4652166A1 (en) 2023-01-18 2025-11-26 Galapagos N.V. Pharmaceutical compositions and solid forms of compound 1 with fumarate for the treatment of inflammatory disorders
CN120584114A (zh) 2023-01-19 2025-09-02 加拉帕戈斯股份有限公司 用于治疗过敏性疾病、炎症性疾病、代谢性疾病、自身炎症性疾病、自身免疫性疾病和增生性疾病的咪唑并[4,5-b]吡啶衍生物
WO2026098666A1 (zh) * 2024-11-11 2026-05-15 杭州领业医药科技有限公司 一种tyk2抑制剂的共晶及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2567552T3 (es) 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
GB201401086D0 (en) 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (en) * 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
US12472181B2 (en) 2025-11-18
SG11202003516TA (en) 2020-05-28
GB201717260D0 (en) 2017-12-06
KR102757425B1 (ko) 2025-01-20
PT3697784T (pt) 2024-01-09
RS64800B1 (sr) 2023-11-30
IL302615B1 (en) 2024-06-01
EP4265254A3 (en) 2024-03-13
AU2023201522A1 (en) 2023-04-13
LT3697784T (lt) 2023-10-25
CN117534670A (zh) 2024-02-09
RU2020116376A (ru) 2021-11-22
IL302615A (en) 2023-07-01
FI3697784T5 (fi) 2024-01-12
IL273943A (en) 2020-05-31
AR113784A1 (es) 2020-06-10
JP7292271B2 (ja) 2023-06-16
SMT202300377T1 (it) 2024-01-10
MY205443A (en) 2024-10-22
EP3697784B1 (en) 2023-10-04
SI3697784T1 (sl) 2023-11-30
CN111225916B (zh) 2023-11-03
IL302615B2 (en) 2024-10-01
CN111225916A (zh) 2020-06-02
KR20200074178A (ko) 2020-06-24
JP2020537672A (ja) 2020-12-24
WO2019076716A1 (en) 2019-04-25
CA3079449A1 (en) 2019-04-25
PL3697784T3 (pl) 2024-03-11
CO2020005200A2 (es) 2020-05-29
IL273943B2 (en) 2023-10-01
US20210169879A1 (en) 2021-06-10
US11564923B2 (en) 2023-01-31
ZA202002166B (en) 2021-05-26
DK3697784T5 (da) 2024-01-15
EP4265254A2 (en) 2023-10-25
TWI805629B (zh) 2023-06-21
TWI866258B (zh) 2024-12-11
AU2018350592B2 (en) 2022-12-22
TW201918483A (zh) 2019-05-16
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
HRP20231315T1 (hr) 2024-02-16
US20230310433A1 (en) 2023-10-05
MA50391A (fr) 2021-04-21
FI3697784T3 (fi) 2023-10-31
HUE063998T2 (hu) 2024-02-28
AU2023201522B2 (en) 2024-11-28
MX2020003863A (es) 2020-08-13
EP3697784A1 (en) 2020-08-26
RU2020116376A3 (cg-RX-API-DMAC7.html) 2021-11-22
TW202411229A (zh) 2024-03-16
PH12020550230A1 (en) 2021-02-08
BR112020007541A2 (pt) 2020-09-24
JP7654031B2 (ja) 2025-03-31
JP2023113834A (ja) 2023-08-16
DK3697784T3 (da) 2023-10-30
US20260183288A1 (en) 2026-07-02
AU2018350592A1 (en) 2020-06-04
ES2967432T3 (es) 2024-04-30

Similar Documents

Publication Publication Date Title
WO2019007696A1 (en) NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS
ZA202107444B (en) Nlrp3 inflammasome inhibitors
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA44474B1 (fr) Inhibiteurs de la ferroportine
MA33768B1 (fr) Triazolopyridines
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
PH12020550230A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA34308B1 (fr) Triazolopyridines substituées
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA39018A1 (fr) (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA42988B1 (fr) Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines